The Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency drugs in development market research report provides comprehensive information on the therapeutics under development for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency and features dormant and discontinued products.
GlobalData tracks six drugs in development for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency by six companies/universities/institutes. The top development phase for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency is phase ii with three drugs in that stage. The Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency pipeline products market are: Sanofi, PTC Therapeutics and Voyager Therapeutics.
The key targets in the Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency pipeline products market include Aromatic L Amino Acid Decarboxylase (AADC or Dopa Decarboxylase or DDC or EC 4.1.1.28).
The key mechanisms of action in the Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency pipeline product include Aromatic L Amino Acid Decarboxylase (AADC or Dopa Decarboxylase or DDC or EC 4.1.1.28) Activator with five drugs in Phase II. The Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency pipeline products include two routes of administration with the top ROA being Intracerebral and one key molecule types in the Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency pipeline products market including Gene Therapy.
Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency overview
Aromatic l-amino acid decarboxylase (AADC) deficiency is a disease that affects the production of signals that allow cells in the nervous system to communicate with each other. This is a rare neurotransmitter disorder. AADC is the last enzyme in the biosynthesis of dopamine and serotonin. The deficiency of AADC leads to metabolic disturbance of dopamine, norepinephrine, epinephrine, and serotonin.
For a complete picture of Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
